Article
Oncology
Emmanuel Bachy, Vincent Camus, Catherine Thieblemont, David Sibon, Rene-Olivier Casasnovas, Loic Ysebaert, Gandhi Damaj, Stephanie Guidez, Gian Matteo Pica, Won Seog Kim, Soon Thye Lim, Marc Andre, Alejandro Martin Garcia-Sancho, Maria Jesus Penarrubia, Philipp B. Staber, Judith Trotman, Andreas Huettmann, Vittorio Stefoni, Alessandro Re, Philippe Gaulard, Marie-Helene Delfau-Larue, Laurence de Leval, Michel Meignan, Ju Li, Franck Morschhauser, Richard Delarue
Summary: This study is a randomized phase III study comparing Ro-CHOP with CHOP in previously untreated adult PTCL patients. The study results showed that the addition of romidepsin to CHOP did not improve PFS, response rates, nor overall survival and increased the frequency of grade >= 3 treatment-emergent adverse events.
JOURNAL OF CLINICAL ONCOLOGY
(2022)
Article
Oncology
Grzegorz S. Nowakowski, Annalisa Chiappella, Randy D. Gascoyne, David W. Scott, Qingyuan Zhang, Wojciech Jurczak, Muhit Ozcan, Xiaonan Hong, Jun Zhu, Jie Jin, David Belada, Juan Miguel Bergua, Francesco Piazza, Heidi Mocikova, Anna Lia Molinari, Dok Hyun Yoon, Federica Cavallo, Monica Tani, Kazuhito Yamamoto, Koji Izutsu, Koji Kato, Myron Czuczman, Sarah Hersey, Adrian Kilcoyne, Jacqueline Russo, Krista Hudak, Jingshan Zhang, Steve Wade, Thomas E. Witzig, Umberto Vitolo
Summary: The ROBUST study aimed to compare the efficacy of lenalidomide plus R-CHOP with placebo/R-CHOP in previously untreated ABC-type DLBCL. While the primary end point of progression-free survival (PFS) was not met in all patients, there were trends favoring R2-CHOP over placebo/R-CHOP in patients with higher-risk disease. The safety profile of R2-CHOP was consistent with individual treatments with no new safety signals.
JOURNAL OF CLINICAL ONCOLOGY
(2021)
Article
Oncology
Grace T. Baek, Noah J. Mathis, Anthony J. Perissinotti, Bernard L. Marini, Anna Brown, Tycel J. Phillips, Ryan A. Wilcox, Victoria R. Nachar
Summary: Bendamustine may lead to a higher rate of prolonged lymphocytopenia and late-onset neutropenia in patients with indolent non-Hodgkin's lymphoma, compared to other chemotherapy regimens. The incidence of late-onset infections did not differ significantly between bendamustine-based regimens and CHOP/CVP.
LEUKEMIA & LYMPHOMA
(2021)
Article
Oncology
Richard A. Newcomb, P. Connor Johnson, Daniel Yang, Katherine Holmbeck, Joanna Choe, Anisa Nabily, Porsha Lark, Tejaswini Dhawale, Hermioni L. Amonoo, Areej El-Jawahri
Summary: Patients with indolent non-Hodgkin's lymphomas (iNHL) report significant psychological distress, a diversity of coping strategies, and complex cognitive understanding of their prognosis. Interventions that address prognostic uncertainty and promote positive emotional coping with prognosis may ameliorate psychological distress in this population.
Article
Medicine, Research & Experimental
Stamatis J. Karakatsanis, Maria Bouzani, Argyris Symeonidis, Maria K. Angelopoulou, Sotirios G. Papageorgiou, Michail Michail, Gabriella Gainaru, Georgia Kourti, Sotirios Sachanas, Christina Kalpadakis, Eirini Katodritou, Theoni Leonidopoulou, Ioannis Kotsianidis, Eleftheria Hatzimichael, Maria Kotsopoulou, Maria Dimou, Eleni Variamis, Dimitrios Boutsis, Nick Kanellias, Maria N. Dimopoulou, Evridiki Michali, George Karianakis, Pantelis Tsirkinidis, Chryssa Vadikolia, Christos Poziopoulos, Anna Pigaditou, Effimia Vrakidou, Theophanis Economopoulos, Lydia Kyriazopoulou, Marina P. Siakantaris, Marie-Christine Kyrtsonis, Konstantinos Anargyrou, Maria Papaioannou, Evdoxia Hatjiharissi, Elissavet Vervessou, Maria Tsirogianni, Maria Palassopoulou, Ekaterini Stefanoudaki, Panayiotis Zikos, Panayiotis Tsirigotis, Gerassimos Tsourouflis, Theodora Assimakopoulou, Evgenia Verrou, Helen Papadaki, Polixeni Lampropoulou, Meletios-Athanasios Dimopoulos, Vassiliki Pappa, Kostas Konstantopoulos, Themis Karmiris, Paraskevi Roussou, Panayiotis Panayiotidis, Gerassimos A. Pangalis, Theodoros P. Vassilakopoulos
Summary: Both R-CHOP-14 and R-CHOP-21 are likely equally effective in PMLBCL patients, but further studies are needed to determine if dose-dense regimens can provide better disease control and long-term outcomes.
Article
Hematology
Mary Gleeson, Nicholas Counsell, David Cunningham, Anthony Lawrie, Laura Clifton-Hadley, Eliza Hawkes, Andrew McMillan, Kirit M. Ardeshna, Cathy Burton, Nick Chadwick, Joanna Gambell, Paul Smith, Paul Mouncey, Christopher Pocock, John Radford, John Davies, Deborah Turner, Anton Kruger, Peter Johnson, David Linch
Summary: The study compared the IPI, R-IPI, and aa-IPI as prognostic indices for DLBCL patients in the UK NCRI trial, finding that R-IPI and aa-IPI did not show significant improvement over IPI in predicting overall and progression-free survival. The study suggests the need for a novel prognostic tool to better identify high-risk DLBCL patients in the rituximab era, despite current support for the use of IPI.
BRITISH JOURNAL OF HAEMATOLOGY
(2021)
Article
Medicine, General & Internal
Stephen M. Ansell, John Radford, Joseph M. Connors, Monika Dlugosz-Danecka, Won-Seog Kim, Andrea Gallamini, Radhakrishnan Ramchandren, Jonathan W. Friedberg, Ranjana Advani, Martin Hutchings, Andrew M. Evens, Piotr Smolewski, Kerry J. Savage, Nancy L. Bartlett, Hyeon-Seok Eom, Jeremy S. Abramson, Cassie Dong, Frank Campana, Keenan Fenton, Markus Puhlmann, David J. Straus
Summary: The study found that using A+AVD for the treatment of stage III or IV Hodgkin's lymphoma provides a survival advantage over ABVD.
NEW ENGLAND JOURNAL OF MEDICINE
(2022)
Article
Multidisciplinary Sciences
I Hadi, A. Schummer, M. Dreyling, C. Eze, R. Bodensohn, O. Roengvoraphoj, C. Belka, M. Li
Summary: This study analyzed the effectiveness and toxicities of radiotherapy in indolent non-Hodgkin's lymphoma (iNHL) patients treated in the institution. The results showed that radiotherapy was highly effective for early stage iNHL treatment with low toxicity. Younger patients had significantly superior progression-free survival (PFS) compared to older patients.
SCIENTIFIC REPORTS
(2021)
Article
Hematology
Guillermo Villacampa, Rodrigo Dienstmann, Francesc Bosch, Pau Abrisqueta
Summary: A systematic review and meta-analysis found that adding molecular targeted agents to R-CHOP in DLBCL patients may only slightly improve progression-free survival (PFS). Younger patients may benefit more, but with a higher rate of adverse events.
ANNALS OF HEMATOLOGY
(2021)
Article
Medicine, Research & Experimental
Keigo Fujishita, Sando Yasuhisa, Satoshi Oka, Yuka Fujisawa, Takuya Machida, Toshi Imai
Summary: This study investigated the effects of extending the interval of R-CHOP therapy on the prognoses of patients with non-indolent non-Hodgkin's B-cell lymphoma. The results showed that patients with intervals of >= 4 weeks were older, had longer follow-up periods and lower relative dose intensity. However, there was no significant difference in the 3-year overall survival rate compared to patients with intervals < 4 weeks.
ACTA MEDICA OKAYAMA
(2022)
Article
Medicine, General & Internal
Herve Tilly, Franck Morschhauser, Laurie H. Sehn, Jonathan W. Friedberg, M. Trneny, Jeff P. Sharman, Charles Herbaux, John M. Burke, Matthew Matasar, Shinya Rai, Koji Izutsu, Neha Mehta-Shah, Lucie Oberic, Adrien Chauchet, Wojciech Jurczak, Yuqin Song, Richard Greil, Larysa Mykhalska, Juan M. Bergua-Burgues, Matthew C. Cheung, Antonio Pinto, Ho-Jin Shin, Greg Hapgood, Eduardo Munhoz, Pau Abrisqueta, Jyh-Pyng Gau, Jamie Hirata, Yanwen Jiang, Mark Yan, Calvin Lee, Christopher R. Flowers, Gilles Salles
Summary: In untreated intermediate-risk or high-risk DLBCL patients, those who received pola-R-CHP had a lower risk of disease progression, relapse, or death compared to those who received R-CHOP. Overall survival and safety profiles were similar between the two groups.
NEW ENGLAND JOURNAL OF MEDICINE
(2022)
Article
Oncology
Yaxiao Lu, Jingwei Yu, Wenchen Gong, Liping Su, Xiuhua Sun, Ou Bai, Hui Zhou, Xue Guan, Tingting Zhang, Lanfang Li, Lihua Qiu, Zhengzi Qian, Shiyong Zhou, Bin Meng, Xiubao Ren, Xianhuo Wang, Huilai Zhang
Summary: The study aimed to evaluate the prognostic value of peripheral blood T lymphocyte subsets in FL patients and develop a predictive model (ICPI) for PFS. The ICPI demonstrated improved prognostic performance and could guide personalized therapy for patients treated with R-CHOP/CHOP chemotherapy.
FRONTIERS IN ONCOLOGY
(2021)
Article
Medicine, Research & Experimental
Yuqin Song, Hui Zhou, Huilai Zhang, Wei Liu, Yuerong Shuang, Keshu Zhou, Fangfang Lv, Hao Xu, Jianfeng Zhou, Wei Li, Huaqing Wang, Hongyu Zhang, Haiwen Huang, Qingyuan Zhang, Wei Xu, Zheng Ge, Ying Xiang, Shuye Wang, Da Gao, Shun'e Yang, Jinying Lin, Lin Wang, Liqun Zou, Meifang Zheng, Jing Liu, Zonghong Shao, Ying Pang, Ruixiang Xia, Zhendong Chen, Ming Hou, Hongxia Yao, Ru Feng, Zhen Cai, Mingzhi Zhang, Wenhua Ran, Lin Liu, Shan Zeng, Wei Yang, Peng Liu, Aibin Liang, Xuelan Zuo, Qingfeng Zou, Junxun Ma, Wei Sang, Ye Guo, Wei Zhang, Yongqing Cao, Yan Li, Jifeng Feng, Xin Du, Xiaohong Zhang, Hongguo Zhao, Hui Zhou, Jie Yu, Xing Sun, Jun Zhu, Lugui Qiu
Summary: The study demonstrated that IBI301 and rituximab showed similar efficacy and safety in previously untreated DLBCL patients, indicating that IBI301 plus CHOP could be a potential treatment regimen for this patient population.
ADVANCES IN THERAPY
(2021)
Article
Hematology
Peter Martin, Nancy L. Bartlett, Julio C. Chavez, John L. Reagan, Sonali M. Smith, Ann S. LaCasce, Jeffrey Jones, James Drew, Chengqing Wu, Erin Mulvey, Maria Revuelta, Leandro Cerchietti, John P. Leonard
Summary: This study investigates the use of CC-486 (oral azacitidine) in combination with R-CHOP in previously untreated intermediate- to high-risk DLBCL or grade 3B/transformed follicular lymphoma. The results show that CC-486 can be safely administered before R-CHOP and has a high overall response rate in these patients.
Article
Medicine, Research & Experimental
Divya Samineni, Weize Huang, Leonid Gibiansky, Hao Ding, Rong Zhang, Chunze Li, Arijit Sinha, Richa Rajwanshi, Kathryn Humphrey, Alexandra Bazeos, Ahmed Hamed Salem, Dale Miles
Summary: Population pharmacokinetics and exposure-response analyses were conducted for venetoclax in combination with R-CHOP in NHL patients, showing no significant association between venetoclax exposure and progression-free survival or adverse events, supporting the selection of 800 mg venetoclax with R-CHOP for future studies in 1L DLBCL patients.
ADVANCES IN THERAPY
(2022)
Article
Hematology
Akihiko Sawaki, Kana Miyazaki, Motoko Yamaguchi, Toshifumi Takeuchi, Kyoko Kobayashi, Hiroshi Imai, Isao Tawara, Ryoichi Ono, Tetsuya Nosaka, Naoyuki Katayama
INTERNATIONAL JOURNAL OF HEMATOLOGY
(2020)
Article
Pathology
Naoto Kuroda, Kiril Trpkov, Yuan Gao, Maria Tretiakova, Yajuan J. Liu, Monika Ulamec, Kengo Takeuchi, Abbas Agaimy, Christopher Przybycin, Cristina Magi-Galluzzi, Soichiro Fushimi, Fumiyoshi Kojima, Malthide Sibony, Jen-Fan Hang, Chin-Chen Pan, Asli Yilmaz, Farshid Siadat, Emiko Sugawara, Pierre-Alexandre Just, Nikola Ptakova, Ondrej Hes
Article
Hematology
Hyera Kim, Hyehyun Jeong, Motoko Yamaguchi, Insuk Sohn, Sang Eun Yoon, Seonggyu Byeon, Joon Young Hur, Youngil Koh, Sung-Soo Yoon, Eo Jin Kim, Masahiko Oguchi, Kana Miyazaki, Senzo Taguchi, Dok Hyun Yoon, Junhun Cho, Young Hyeh Ko, Seok Jin Kim, Ritsuro Suzuki, Won Seog Kim
Article
Oncology
Aya Ebina, Yuki Togashi, Satoko Baba, Yukiko Sato, Seiji Sakata, Masashi Ishikawa, Hiroki Mitani, Kengo Takeuchi, Iwao Sugitani
Article
Oncology
Reiji Fukano, Tetsuya Mori, Masahiro Sekimizu, Ilseung Choi, Akiko Kada, Akiko Moriya Saito, Ryuta Asada, Kengo Takeuchi, Takashi Terauchi, Ukihide Tateishi, Keizo Horibe, Hirokazu Nagai
Article
Oncology
Ines P. Nearchou, Hideki Ueno, Yoshiki Kajiwara, Kate Lillard, Satsuki Mochizuki, Kengo Takeuchi, David J. Harrison, Peter D. Caie
Summary: This study developed a deep learning algorithm to assist in the objective and standardized assessment of DR in CRC patients, showing its superior prognostic significance compared to manual assessment. The findings highlight the potential of using machine learning approaches for more accurate patient stratification in CRC.
Article
Medicine, General & Internal
Yuria Egusa, Midori Filiz Nishimura, Satoko Baba, Kengo Takeuchi, Takuma Makino, Tomoyasu Tachibana, Asami Nishikori, Azusa Fujita, Hiroyuki Yanai, Yasuharu Sato
Summary: Secretory carcinoma is a salivary gland neoplasm with specific cytological and histological findings, reliant on the detection of the ETV6-NTRK3 fusion gene. The study examined four cases of secretory carcinoma involving the parotid gland, all of which displayed papillary and/or dendritic pattern clusters and cytoplasmic vacuolation. Giemsa staining may be helpful in the diagnosis of secretory carcinoma.
Article
Cell Biology
Naoko Tsuyama, Masaaki Noguchi, Reimi Asaka, Seiji Sakata, Satoko Baba, Hiroshi Izumi, Kengo Takeuchi
Summary: Hodgkinoid histiocytosis is a rare condition that mimics classic Hodgkin lymphoma but suggests reactive histiocytic/dendritic cell proliferation in lymph nodes. It is characterized by peripheral lymphadenopathy, blood eosinophilia, and skin manifestations. Pathological examination reveals large histiocytes resembling Hodgkin cells in an inflammatory background. These histiocytes express CD30 but lack other markers, viral association, and genetic mutations commonly seen in Hodgkin lymphoma.
Article
Oncology
Tetsuya Negoto, Minji Jo, Izuma Nakayama, Motohiro Morioka, Kengo Takeuchi, Hiroshi Kawachi, Toru Hirota
Summary: Aneuploidy arises from chromosome segregation errors or chromosomal instability. This study analyzed gastric tumors and found that cancer cells exhibit a significant increase in aneuploid population, particularly in advanced cases. The expansion of aneuploid population is associated with p53 deficiency.
Review
Medicine, General & Internal
Chih-Yi Liu, Nai-Wen Kang, Kengo Takeuchi, Shih-Sung Chuang
Summary: Merkel cell carcinoma (MCC) is an aggressive and potentially metastatic rare primary neuroendocrine carcinoma (NEC) of the skin. Combined MCCs, which have a higher probability of metastasis, may be misdiagnosed due to small or superficial biopsy samples. This case report highlights the importance of timely diagnosis and appropriate management, as well as the presence of both MCC and non-MCC components in metastatic nodes.
Article
Cell Biology
Misayo Miyake, Seiji Sakata, Naoko Tsuyama, Yuki Togashi, Masaaki Noguchi, Nobuhiro Tsukada, Takashi Kumagai, Yuko Mishima, Kengo Takeuchi
Summary: This study presents the first report of nodal marginal zone lymphoma (NMZL) with tissue eosinophilia and highlights the distinctive morphological features and diagnostic factors for this type of lymphoma.
Article
Cell Biology
Kyoko Yamashita, Satoko Baba, Yuki Togashi, Akito Dobashi, Keisuke Ae, Seiichi Matsumoto, Miwa Tanaka, Takuro Nakamura, Kengo Takeuchi
Summary: The aim of this study was to clarify the genetic and pathological spectrum of AFST and determine whether histiocytic marker-positive cells are true neoplastic cells. The most frequent fusion gene in AFST was reported to be AHRR::NCOA2, with AHRR::NCOA3 potentially being the second most common fusion gene. Immunohistochemical analysis showed that CD163- and CD68-positive cells were diffusely distributed in all 12 cases, while varying levels of desmin-positive cells were observed in 9 cases. Double immunofluorescence staining and immunofluorescence in situ hybridisation confirmed the differences between CD163-positive cells and desmin-positive cells with AHRR::NCOA2 fusion in all 4 cases.
Editorial Material
Hematology
Kennosuke Karube, Kengo Takeuchi
Editorial Material
Hematology
Kentaro Narita, Kengo Takeuchi
Article
Medicine, General & Internal
Emiko Sugawara, Yasuyuki Shigematsu, Gulanbar Amori, Keisuke Sugita, Junji Yonese, Kengo Takeuchi, Kentaro Inamura
Summary: This study characterized the immunohistochemical and morphological characteristics of female urethral adenocarcinoma using 9 cases. Two subtypes of adenocarcinoma with distinct staining patterns were identified: the CDX2- and PAX8-expressing subtype and the clear cell carcinoma marker-expressing subtype. These findings are important for the accurate diagnosis of this rare tumor type.